> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Wegovy, Ozempic Shortages Resolved: FDA
- URL: https://www.fdaweb.com/wegovy-ozempic-shortages-resolved-fda/
- Published: 2025-02-21T12:00:00.000Z
- Updated: 2026-09-14T14:53:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158699

FDA [has determined](https://www.fda.gov/media/185526/download?attachment&ref=fdaweb.com) the shortage of [semaglutide](https://dps.fda.gov/drugshortages/activeingredient/semaglutide-injection?ref=fdaweb.com) injection products (Novo Nordisk’s Wegovy and Ozempic) is resolved. “FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” an [agency notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize?utm%5Fmedium=email&utm%5Fsource=govdelivery) says. “Patients and prescribers may still see intermittent and limited localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.”

The agency says it is also exercising limited enforcement discretion against compounders for violations of the FD&C Act in the following scenarios:

- A state-licensed pharmacy or physician compounding semaglutide injection products that are essentially a copy of an FDA-approved product until 4/22.
- Outsourcing facilities under section 503B of the FD&C Act compounding semaglutide injection products that are essentially a copy of an FDA-approved drug product until 5/22.

“FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe,” the notice says.